393509-05-2 Usage
Description
(R)-2-(5-broMo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is a complex organic chemical compound with a carboxylic acid functional group and a cyclopenta[b]indol-3-yl core. It is characterized by the presence of bromine, chlorine, and fluorine atoms, which may contribute to its pharmacological properties and metabolic stability. (R)-2-(5-broMo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is considered a potential pharmaceutical intermediate or active pharmaceutical ingredient (API), suitable for drug development.
Uses
Used in Pharmaceutical Industry:
(R)-2-(5-broMo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is used as a potential pharmaceutical intermediate or active pharmaceutical ingredient (API) for drug development. Its carboxylic acid functional group and cyclopenta[b]indol-3-yl core suggest potential activity as an agonist or antagonist at various receptors, such as serotonin receptors. The presence of bromine, chlorine, and fluorine atoms in the molecule may also enhance its pharmacological properties or metabolic stability.
Used in Drug Development Research:
In the field of drug development research, (R)-2-(5-broMo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is used as a compound for further research and testing. Its unique structure and functional groups make it a promising candidate for exploring its potential uses and properties in the context of drug development. This may include investigating its interactions with various receptors, its efficacy in treating specific conditions, and its safety profile.
Used in Medicinal Chemistry:
(R)-2-(5-broMo-4-(4-chlorobenzyl)-7-fluoro-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid is utilized in medicinal chemistry as a compound with potential therapeutic applications. Its structural features, including the carboxylic acid group and the presence of halogen atoms, make it an interesting molecule for studying its interactions with biological targets and its potential to be optimized for specific therapeutic purposes.
Check Digit Verification of cas no
The CAS Registry Mumber 393509-05-2 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 3,9,3,5,0 and 9 respectively; the second part has 2 digits, 0 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 393509-05:
(8*3)+(7*9)+(6*3)+(5*5)+(4*0)+(3*9)+(2*0)+(1*5)=162
162 % 10 = 2
So 393509-05-2 is a valid CAS Registry Number.
393509-05-2Relevant articles and documents
Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chlorobenzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4- tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524)
Sturino, Claudio F.,O'Neill, Gary,Lachance, Nicolas,Boyd, Michael,Berthelette, Carl,Labelle, Marc,Li, Lianhai,Roy, Bruno,Scheigetz, John,Tsou, Nancy,Aubin, Yves,Bateman, Kevin P.,Chauret, Nathalie,Day, Stephen H.,Lévesque, Jean-Fran?ois,Seto, Carmai,Silva, Jose H.,Trimble, Laird A.,Carriere, Marie-Claude,Denis, Danielle,Greig, Gillian,Kargman, Stacia,Lamontagne, Sonia,Mathieu, Marie-Claude,Sawyer, Nicole,Slipetz, Deborah,Abraham, William M.,Jones, Tom,McAuliffe, Malia,Piechuta, Hana,Nicoll-Griffith, Deborah A.,Wang, Zhaoyin,Zamboni, Robert,Young, Robert N.,Metters, Kathleen M.
, p. 794 - 806 (2007/10/03)
The discovery of the potent and selective prostaglandin D2 (PGD2) receptor (DP) antagonist [(3R)-4-(4-chlorobenzyl)-7-fluoro-5- (methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (13) is presented. Initial lead antagonists 6 and 7 were found to be potent and selective DP antagonists (DP Ki = 2.0 nM for each); however, they both suffered from poor pharmacokinetic profiles, short half-lives and high clearance rates in rats. Rat bile duct cannulation studies revealed that high concentrations of parent drug were present in the biliary fluid (Cmax = 1100 μM for 6 and 3900 μM for 7). This pharmacokinetic liability was circumvented by replacing the 7-methylsulfone substituent present in 6 and 7 with a fluorine atom resulting in antagonists with diminished propensity for biliary excretion and with superior pharmacokinetic profiles. Further optimization led to the discovery of the potent and selective DP antagonist 13.
NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
-
, (2008/06/13)
The present invention encompasses compounds of Formula I: as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.
NIACIN RECEPTOR AGONISTS, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF TREATMENT
-
Page/Page column 77, (2010/11/08)
The present invention encompasses compounds of Formula (I); as well as pharmaceutically acceptable salts and hydrates thereof, that are useful for treating dyslipidemias. Pharmaceutical compositions and methods of use are also included.
